Investigational drug · Phase 2
MTX-001
Also called: human amniotic fluid
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Venous Stasis Ulcer, Venous Leg Ulcer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MTX-001"
First trial start
2022
Feb 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MTX-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Stasis Ulcer
- Venous Leg Ulcer
Largest trials
Live from ClinicalTrials.gov: studies naming "MTX-001" as an intervention, largest first.
Merakris TherapeuticsIndustry
NCT04647240 · 80 participants (planned) · Start Feb 26, 2022 · Primary completion Mar 31, 2027
Drug: MTX-001 (human amniotic fluid) · For: Venous Stasis Ulcer; Venous Leg Ulcer
Sites: Tucson, Arizona; Castro Valley, California; Los Angeles, California · 12 sites in all
Merakris TherapeuticsIndustry
NCT06730022
Drug: MTX-001 (Dermacyte Liquid) · For: Cutaneous Ulcer; Diabetic Ulcer; Surgical Wound Dehiscence and 4 more
Sites: Arvada, Colorado
Newest research
PubMed records naming it or its code names, newest first.
- Identification of gestational-age-dependent cell-free fetal mRNA transcriptional changes in human amniotic fluid.
Eishi C, Miura S, Nagata K, et al. · J Hum Genet 2026
- Application of non-targeted analysis for the identification of novel environmental contaminants in amniotic fluid.
Ji X, Shear M, Abrahamsson D, et al. · J Expo Sci Environ Epidemiol 2026
- A photopatternable multiplex GelMA platform for studying small EV-brain endothelial interactions and direction-resolved glioblastoma spheroid outgrowth.
Hosseini Karimi SN, Bedikyan N, Özten MA, et al. · Biomater Sci 2026
- Human amniotic fluid stem cell-derived extracellular vesicles enhance enteric neural crest cell extension following transplantation into aganglionic mouse gut.
Nakazawa-Tanaka N, Fujiwara N, Miyahara K, et al. · Pediatr Surg Int 2026
- Comparison of the Effects of Human Amniotic Fluid-Derived Cell Culture Medium and Adipose Tissue-Derived Stem Cells on Capsule Formation Around Silicone Prosthesis.
Aghazada TM, Guler EM, Hekimoglu ER, et al. · Aesthetic Plast Surg 2026
- Research hotspots and evolution trends of human amniotic fluid stem cells: A cite space bibliometric analysis based on WoSCC and PubMed.
Lou H, Wang Z, Zhang S, et al. · Medicine (Baltimore) 2026
Also in development for Venous Stasis Ulcer
- TR987 0.1%Phase 32 trials
TR Therapeutics · Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.